CPSE:ALK B

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ALK-Abelló A/S, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally. More Details

Rewards

Earnings are forecast to grow 59.21% per year

Became profitable this year

Risk Analysis

No risks detected for ALK B from our risk checks.


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has ALK-Abelló's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALK B is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: ALK B's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

0.09%

ALK B

1.0%

DK Pharmaceuticals

0.5%

DK Market


1 Year Return

30.2%

ALK B

-1.5%

DK Pharmaceuticals

22.8%

DK Market

Return vs Industry: ALK B exceeded the Danish Pharmaceuticals industry which returned -1.5% over the past year.

Return vs Market: ALK B exceeded the Danish Market which returned 22.8% over the past year.


Shareholder returns

ALK BIndustryMarket
7 Day0.09%1.0%0.5%
30 Day0.5%4.6%4.6%
90 Day9.1%-1.5%6.8%
1 Year30.2%30.2%1.7%-1.5%25.2%22.8%
3 Year190.2%190.2%26.6%11.9%50.7%39.0%
5 Year150.5%147.9%28.0%6.2%53.0%33.5%

Long-Term Price Volatility Vs. Market

How volatile is ALK-Abelló's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ALK-Abelló undervalued compared to its fair value and its price relative to the market?

546.07x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: ALK B (DKK2142) is trading above our estimate of fair value (DKK2032.22)

Significantly Below Fair Value: ALK B is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ALK B is poor value based on its PE Ratio (546.1x) compared to the XE Pharmaceuticals industry average (23.1x).

PE vs Market: ALK B is poor value based on its PE Ratio (546.1x) compared to the Danish market (17x).


Price to Earnings Growth Ratio

PEG Ratio: ALK B is poor value based on its PEG Ratio (9.2x)


Price to Book Ratio

PB vs Industry: ALK B is overvalued based on its PB Ratio (7.3x) compared to the XE Pharmaceuticals industry average (3.5x).


Next Steps

Future Growth

How is ALK-Abelló forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

59.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALK B's forecast earnings growth (59.2% per year) is above the savings rate (0.3%).

Earnings vs Market: ALK B's earnings (59.2% per year) are forecast to grow faster than the Danish market (11.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ALK B's revenue (11% per year) is forecast to grow faster than the Danish market (6.4% per year).

High Growth Revenue: ALK B's revenue (11% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALK B's Return on Equity is forecast to be low in 3 years time (9.7%).


Next Steps

Past Performance

How has ALK-Abelló performed over the past 5 years?

-54.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALK B has high quality earnings.

Growing Profit Margin: ALK B became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ALK B's earnings have declined by 54.8% per year over the past 5 years.

Accelerating Growth: ALK B has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ALK B has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13.1%).


Return on Equity

High ROE: ALK B's Return on Equity (1.3%) is considered low.


Next Steps

Financial Health

How is ALK-Abelló's financial position?


Financial Position Analysis

Short Term Liabilities: ALK B's short term assets (DKK2.3B) exceed its short term liabilities (DKK976.0M).

Long Term Liabilities: ALK B's short term assets (DKK2.3B) exceed its long term liabilities (DKK1.4B).


Debt to Equity History and Analysis

Debt Level: ALK B's debt to equity ratio (22.1%) is considered satisfactory.

Reducing Debt: ALK B's debt to equity ratio has reduced from 25.5% to 22.1% over the past 5 years.

Debt Coverage: ALK B's debt is well covered by operating cash flow (42%).

Interest Coverage: ALK B's interest payments on its debt are well covered by EBIT (3.3x coverage).


Balance Sheet


Next Steps

Dividend

What is ALK-Abelló current dividend yield, its reliability and sustainability?

0.11%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALK B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALK B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALK B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALK B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: ALK B is not paying a notable dividend for the Danish market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALK B's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Carsten Hellmann (56 yo)

4.58yrs

Tenure

Mr. Carsten Hellmann has been the Chief Executive Officer and President at ALK-Abelló A/S since May 17, 2016. Mr. Hellmann serves as the Chief Executive Officer at Merial Inc., Boehringer Ingelheim Animal ...


Leadership Team

NamePositionTenureCompensationOwnership
Katja Thalund
Senior CMC Project Manager & Independent Director9.92yrskr.275.00k0.00022%
DKK 51.3k
Carsten Hellmann
President4.58yrsno data0.019%
DKK 4.4m
Søren Jelert
Group CFO3.08yrsno datano data
Henrik Jacobi
Executive VP of Research & Development and Member of Board of Managementno datano data0.0055%
DKK 1.3m
Søren Niegel
Executive VP of Commercial Operations & Member of Management Board8.58yrsno data0.019%
DKK 4.3m
Per Plotnikof
Vice President of Corporate Communicationsno datano datano data
Hendrik Nolte
Senior Vice President of Research & Development - North America and International Markets3.75yrsno datano data
Christian Houghton
Head of Product Supply1.92yrsno datano data
Miles Guralnick
President of ALK Abelló Source Materials Incno datano datano data

3.8yrs

Average Tenure

51yo

Average Age

Experienced Management: ALK B's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Katja Thalund
Senior CMC Project Manager & Independent Director9.92yrskr.275.00k0.00022%
DKK 51.3k
Lene Skole-Sørensen
Vice Chairman of the Board5.75yrskr.650.00k0.011%
DKK 2.5m
Anders Hedegaard
Chairman of the Board0.75yrno datano data
Lars Holmqvist
Director5.75yrskr.375.00kno data
Jakob Riis
Director7.75yrskr.425.00k0.0050%
DKK 1.2m
Vincent Warnery
Independent Director1.75yrskr.220.00kno data
Nanna Carlson
Independent Director1.75yrskr.220.00kno data
Johan Smedsrud
Independent Director1.75yrskr.220.00kno data

3.8yrs

Average Tenure

53yo

Average Age

Experienced Board: ALK B's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ALK-Abelló A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ALK-Abelló A/S
  • Ticker: ALK B
  • Exchange: CPSE
  • Founded: 1923
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr.23.295b
  • Shares outstanding: 10.92m
  • Website: https://www.alk.net

Number of Employees


Location

  • ALK-Abelló A/S
  • Boge Alle 6-8
  • Horsholm
  • Capital Region of Denmark
  • 2970
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALK BCPSE (OMX Nordic Exchange Copenhagen)YesB Ordinary SharesDKDKKDec 2005
0OIRLSE (London Stock Exchange)YesB Ordinary SharesGBDKKDec 2005
4AJDB (Deutsche Boerse AG)YesB Ordinary SharesDEEURDec 2005
AKBL.FOTCPK (Pink Sheets LLC)YesB Ordinary SharesUSUSDDec 2005
ALKBCBATS-CHIXE (BATS 'Chi-X Europe')YesB Ordinary SharesGBDKKDec 2005
AKAB.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDSep 2013

Biography

ALK-Abelló A/S, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally. The company offers allergy immunotherapy ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/03 18:09
End of Day Share Price2020/12/03 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.